Ballast, Inc. Aldeyra Therapeutics, Inc. Transaction History
Ballast, Inc.
- $202 Million
- Q2 2025
A detailed history of Ballast, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Ballast, Inc. holds 31,623 shares of ALDX stock, worth $163,490. This represents 0.06% of its overall portfolio holdings.
Number of Shares
31,623Holding current value
$163,490% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
147Shares Held
39.2MCall Options Held
620KPut Options Held
435K-
Perceptive Advisors LLC New York, NY9.28MShares$48 Million2.23% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$28.3 Million21.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.72MShares$19.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$18.7 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.75MShares$9.05 Million2.26% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $302M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...